X4 파마슈티컬스(XFOR)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.55 (+1.43%), 시가총액 $0.37B, 52주 최저~최고 $1.42 ~ $4.66.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporati
X4 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
X4 파마슈티컬스의 현재 주가는 $3.55 (+1.43%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
X4 파마슈티컬스의 시가총액은 약 $0.37B입니다.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It off